Drugs / Antithymocyte globulin (ATG)-Fresenius
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03963024 Background | Feb 2014 → Jan 2019 | acute leukemia, bone marrow disorder, graft versus host disease, plasma cell myeloma | IRCCS San Raffaele | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antithymocyte globulin (ATG)-Fresenius | “Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2)” NCT03963024 ↗ |
| Route | Intravenous | “Antithymocyte globulin (ATG)-Fresenius i.v.” NCT03963024 ↗ |